Peekcell // A Global Revolution In Early Cancer Detection For Women

Imagine a world where early cancer detection is accessible to every woman, where fear and discomfort no longer stand in the way of life-saving screening. 

Here is the future of women’s health: a breakthrough urine-based test designed to close the critical gaps in early detection, boost participation rates, and transform survival outcomes worldwide. No needles. No delays. Just innovation and the power to act before it is too late.

Cancer remains a leading health threat for women worldwide. According to the World HealthOrganization (WHO), in 2020, breast cancer was the most common cancer in women, with 2.3 million new cases and 685,000 deaths annually. Despite these stark figures, screening participation remains low worldwide. Lack of access to healthcare, cultural stigma, delays in diagnosis and the discomfort of traditional screening methods prevent millions of women from getting tested and contribute to these challenges.

Peekcell’s non-invasive, urine based test detects early cancer biomarkers using advanced AI analysis, offering a painless, accessible, and efficient alternative to traditional screening methods. Women can collect samples at home, and results are delivered quickly, enabling timely medical intervention when needed.

How it works:

• Sample collection: A urine sample is collected at home or in a lab.

• Biomarker analysis: The sample is analyzed for specific cancer biomarkersin a biomedical laboratory.

• AI-powered risk assessment: An AI algorithm calculates a risk score to assist healthcare providers in decision-making.

• Actionable results: Based on the results, women are referred for further testing if cancer is suspected, or encouraged to follow national screening guidelines.

Early detection significantly improves survival rates, from 90% in early stages to just20% in advanced stages. Peekcell’s solution is designed to increase accessibility, reduce delays, and empower women to take control of their health.

Additional information is available here on Peekcell’s website.